Ki-67/MIB-1 as a Prognostic Marker in Cervical Cancer - a Systematic Review with Meta-Analysis


Background: In cervical cancer patients it has been reported that there in a significant Ki-67/MIB-1 expressionis correlated with survival in cervical cancer patients. However, the prognostic value is still not well understood.Materials and
Methods: In the present meta-analysis the prognostic value of Ki-67/MIB-1 with regard to overallsurvival (OS) and disease-free survival (DFS) in cervical cancer was investigated. The databases of PubMed, ISIWeb of Science, Cochrane Central Register of Controlled Trials, EMBASE, Science Direct and Wiley OnlineLibrary were used to identify appropriate literature.
Results: In order to explore the relationship between Ki-67/MIB-1 and cervical cancer, we have included 13 studies covering 894 patients in the current meta-analysis. Theeffect of Ki-67/MIB-1 on OS for pooled random effects HR estimate was 1.63 (95%confidence interval (CI) 1.09-2.45; P<0.05). The pooled HR for DFS was 1.26 (95%CI 0.58-2.73; P>0.05) and the subgroup analysis indicatedKi-67/MIB1 was associated with DFS (HR=3.67, 95%CI 2.65-5.09) in Asians.
Conclusions: According to thismeta-analysis, Ki-67/MIB-1 has prognostic value for OS in patients suffering from cervical cancer. For betterevaluation of the prognostic role of Ki-67/MIB-1 on DFS, studies with larger numbers of patients are needed tovalidate present findings in the future.